Thread: SLNO (MC $24 M) Rare Disease in Phase 3 a Potential Blockbuster =MASSIVE Undervalued

Results 1 to 3 of 3

  1. #1

    Default SLNO (MC $24 M) Rare Disease in Phase 3 a Potential Blockbuster =MASSIVE Undervalued

    Soleno (SLNO) is a new formed company through the merger between Capnia and the private Essentials (merger completed in march 2017) thats why its still undiscovered. SLNO has a potential Blockbuster in Phase 3 for the treatment of Prader Willi Syndrome a Rare Disease for which there is no approved treatments . This unknown low float stock which has a terrible low valuation of $24 million could be the next SRPT the stock should be valued way over $100+ million right now for their Phase 3 Program and in the Billion if the outcome of the Phase 3 trial is positive which expected by next year .MYOK and SRPT both rare disease companies hitting Billion Dollar Valuation after Phase 2 results in just 10 patients , you will not find a rare disease company below $100 million valuation with a potential blockbuster in phase 3 that shows how terrible undervalued this stock is .GL
  2. #2

    Default

    Soleno Therapeutics, Inc. (Soleno) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company is currently advancing its lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, into a Phase III clinical development program at the end of 2017.
  3. #3

    Default

    This product achieved its highest revenue in 2008,with worldwide sales of approximately $900 million.While somatropin has been proven to improve growth and body composition, it does not affect the key disease component of hyperphagia and use is associated with substantial risk. Soleno is developing DCCR for the treatment of PWS,to help address the unmet need of this patient population.

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts